Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Published Results
Trial Contact Information
Related Information
Registry Information

Alternate Title

Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs Phase III Treatment Closed 18 and over NCI NSABP-C-08 NSABP-C-08, NCT00096278

Special Category: CTSU trial, NCI Web site featured trial

Objectives

Primary

1. Compare disease-free survival of patients with resected stage II or III adenocarcinoma of the colon treated with adjuvant chemotherapy comprising fluorouracil, leucovorin calcium, and oxaliplatin with vs without bevacizumab.

Secondary

1. Compare overall survival of patients treated with these regimens.

Tertiary

1. Determine the persistence of proteinuria after completion of bevacizumab in patients treated with bevacizumab.
2. Correlate the development of proteinuria with clinical sequelae in patients treated with bevacizumab.
3. Determine risk factors for development of proteinuria in patients treated with bevacizumab.
4. Determine the effect of discontinuing bevacizumab on hypertension in these patients.
5. Determine the incidence of delayed vascular events (e.g., myocardial infarction, CNS ischemia, and thrombosis) in patients treated with chemotherapy in combination with bevacizumab.
6. Determine the effect of this drug on ovarian function in premenopausal women.
7. Determine the incidence rate of immunogenicity and serum levels of bevacizumab in these patients.

Entry Criteria

Disease Characteristics:

• Histologically confirmed adenocarcinoma of the colon, meeting 1 of the following stage criteria:
  • Stage II disease (T3 or 4, N0, M0)
  • Stage III disease (any T, N1 or 2, M0)



• No rectal tumors
  • Distal extent of tumor ≥ 12 cm from the anal verge by endoscopy or surgical examination



• T4 tumors involving an adjacent structure (e.g., bladder, small intestine, or ovary) by direct extension from the primary tumor are eligible provided the following criteria are met:
  • All or a portion of the adjacent structure was removed en bloc with the primary tumor
  • All grossly visible tumor was completely resected (i.e., curative resection) in the opinion of the surgeon
  • Margins of the resected specimen not involved with malignant cells by pathology
  • Not planning local radiotherapy



• En bloc complete gross resection of tumor by open laparotomy or laparoscopically-assisted colectomy within the past 29-50 days
  • Two-stage surgical procedure allowed (i.e., decompressive colostomy followed by definitive surgical resection)



• Patients with > 1 synchronous primary colon tumor are eligible
  • Disease staging based on more advanced primary tumor



• No isolated, distant, or non-contiguous intra-abdominal metastases, even if resected

Prior/Concurrent Therapy:

Biologic therapy

• No concurrent prophylactic growth factors
• No concurrent biological response modifiers

Chemotherapy

• Not specified

Endocrine therapy

• Not specified

Radiotherapy

• See Disease Characteristics
• No prior radiotherapy for this malignancy
• No concurrent radiotherapy for this malignancy

Surgery

• See Disease Characteristics
• Recovered from prior surgery
• More than 4 weeks since prior major surgery or open biopsy
• More than 7 days since prior core biopsy or other minor surgery (except placement of a vascular access device)
• No concurrent or anticipated concurrent major surgery

Other

• No prior systemic therapy for this malignancy
• No concurrent halogenated antiviral agents (e.g., sorivudine)
• No other concurrent investigational drugs
• No other concurrent antineoplastic agents

Patient Characteristics:

Age

• 18 and over

Performance status

• ECOG 0-1

Life expectancy

• At least 5 years

Hematopoietic

• Absolute granulocyte count ≥ 1,500/mm³ (unless it represents an ethnic or racial variation of normal)
• Postoperative platelet count ≥ 100,000/mm³
• No significant bleeding unrelated to the primary colon tumor within the past 6 months

Hepatic

• Bilirubin ≤ upper limit of normal (ULN) (unless due to slow conjugation of bilirubin caused by Gilbert's disease or a similar syndrome)
• Alkaline phosphatase < 2.5 times ULN
• AST < 1.5 times ULN
  • If AST > normal, serologic testing for hepatitis B and C is required and the results must be negative
• No PT/INR > 1.5 unless patient is on full-dose anticoagulants AND the following criteria are met:
  • INR 2-3 on a stable dose of warfarin
  • No active bleeding
  • No pathological condition associated with a high risk of bleeding
• No hepatic disease that would preclude study participation
• No history of viral hepatitis or other chronic liver disease

Renal

• Serum creatinine ≤ 1.5 times ULN
• Urine protein/creatinine ratio < 1.0

  OR

• < 1 g of protein on 24-hour urine collection
• No renal disease that would preclude study participation

Cardiovascular

• No uncontrolled blood pressure, defined as > 150/90 mm Hg
• No cardiovascular disease that would preclude study participation, including any of the following:
  • New York Heart Association class III or IV myocardial disease
  • Myocardial infarction within the past 12 months
  • Unstable angina within the past 12 months
  • Symptomatic arrhythmia
• No history of transient ischemic attack or cerebrovascular accident
• No arterial thrombotic event within the past 12 months
• No symptomatic peripheral vascular disease

Other

• No other malignancy within the past 5 years except effectively treated squamous cell or basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum
  • Must be at low risk of recurrence from any prior malignancy
• No serious or non-healing wound, skin ulcer, or bone fracture
• No active gastroduodenal ulcer by endoscopy
• No clinically significant peripheral neuropathy (i.e., neurosensory or neuromotor toxicity ≥ grade 2)
• No significant traumatic injury within the past 4 weeks
• No other nonmalignant systemic disease that would preclude study participation
• No psychiatric or addictive disorder or other condition that would preclude study participation
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
  • Patients randomized to receive bevacizumab must use effective contraception during and for 3 months after study treatment

Expected Enrollment

A total of 2,632 patients (1,316 per treatment arm) will be accrued for this study within 2.5 years.

Outcomes

Disease-free survival as assessed by recurrence, second primary cancer, or death from any cause every 6 months for 4 years

Survival as assessed by death from any cause after 2 years
Treatment related mortality as assessed by CTCAE version 3.0 at 6 months

Outline

This is a randomized, multicenter study. Patients are stratified according to participating center and number of positive lymph nodes (0 vs 1-3 vs > 3). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive adjuvant chemotherapy comprising concurrent oxaliplatin and leucovorin calcium IV over 2 hours on day 1. Patients also receive adjuvant fluorouracil IV over 2-4 minutes on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.



• Arm II: Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive adjuvant oxaliplatin, leucovorin calcium, and fluorouracil as in arm I. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of adjuvant chemotherapy, patients continue to receive bevacizumab alone every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Allegra CJ, Yothers G, O'Connell MJ, et al.: Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. [Abstract] J Clin Oncol 26 (Suppl 15): A-4006, 2008.

Trial Contact Information

Trial Lead Organizations

National Surgical Adjuvant Breast and Bowel Project

Carmen Allegra, MD, Protocol chair		Ph: 301-294-3093

Related Information

Featured trial article

Registry Information
Official Title		A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks with Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients with Resected Stages II and III Carcinoma of the Colon
Trial Start Date		2004-09-15
Registered in ClinicalTrials.gov		NCT00096278
Date Submitted to PDQ		2004-09-01
Information Last Verified		2006-10-06
NCI Grant/Contract Number		CA12027

Back to Top